Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX004903-01A1 |
| Title: | Rational Combination of MAP4K4 Inhibition and Immunotherapy in Pancreatic Cancer |
| Principal Investigator: | Ajay Rana |
| Location: | Chicago, IL |
| Congressional District Code: | 7 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | October 2020 - September 2024 |
| FY 2021 Funding Amount: | $206,800 |
| Total Award Amount (all years): |
$701,800 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Summary/Abstract: Pancreatic Ductal Adenocarcinoma (PDAC) remains remarkably lethal with a 5-year survival rate of less than 9%. Due to its widespread resistance to conventional therapy, PDAC is expected to be the second most common cause of cancer-related death in the United States by 2030. Oncogenic KRAS mutations are nearly uniform in PDAC, affecting over 90% of patients. The mutant KRAS is a key driver in the neoplastic phenotype, and leads to hyper-activation of KRAS, permitting for sustain... |